KTTA - Pasithea Therapeutics Corp

0.7965
0.006   0.816%

Share volume: 82,290
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$0.79
0.01
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 43%
Dept financing 20%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.87%
1 Month
9.11%
3 Months
-31.92%
6 Months
4.87%
1 Year
-28.24%
2 Year
-89.38%
Key data
Stock price
$0.80
P/E Ratio 
0.00
DAY RANGE
$0.77 - $0.80
EPS 
-$7.76
52 WEEK RANGE
$0.28 - $3.79
52 WEEK CHANGE
-$28.24
MARKET CAP 
5.447 M
YIELD 
N/A
SHARES OUTSTANDING 
7.444 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
-0.04
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$76,057
AVERAGE 30 VOLUME 
$151,161
Company detail
CEO: Tiago R. Marques
Region: US
Website: pasithea.com
Employees: 3
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Pasithea Therapeutics Corp. engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.

Recent news